Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections

Wyeth is now a wholly owned subsidiary of Pfizer314 enrolled

Overview

Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

314

Conditions

Diabetes Mellitus Diabetic Foot

Interventions

Piperacillin/TazobactamDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Patients with diabetes mellitus * Inpatient * Have 1 or more infected ulcer(s) below the ankle Exclusion Criteria * Must not have gangrene or severely impaired arterial supply in your foot * Must not have a bone infection in the area of your ulcer * Must not have allergies to penicillins

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.